» Articles » PMID: 35544131

Comparison of Hepatic Arterial Infusion Pump Chemotherapy Vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma

Abstract

Importance: Intrahepatic cholangiocarcinoma (iCCA) is often multifocal (ie, satellites or intrahepatic metastases) at presentation.

Objective: To compare the overall survival (OS) of patients with multifocal iCCA after hepatic arterial infusion pump (HAIP) floxuridine chemotherapy vs resection.

Design, Setting, And Participants: In this cohort study, patients with histologically confirmed, multifocal iCCA were eligible. The HAIP group consisted of consecutive patients from a single center who underwent HAIP floxuridine chemotherapy for unresectable multifocal iCCA between January 1, 2001, and December 31, 2018. The resection group consisted of consecutive patients from 12 centers who underwent a curative-intent resection for multifocal iCCA between January 1, 1990, and December 31, 2017. Resectable metastatic disease to regional lymph nodes and previous systemic therapy were permitted. Patients with distant metastatic disease (ie, stage IV), those who underwent resection before starting HAIP floxuridine chemotherapy, and those who received a liver transplant were excluded. Data were analyzed on September 1, 2021.

Main Outcomes And Measures: Overall survival in the 2 treatment groups was compared using the Kaplan-Meier method and log-rank test.

Results: A total of 319 patients with multifocal iCCA were included: 141 in the HAIP group (median [IQR] age, 62 [53-70] years; 79 [56.0%] women) and 178 in the resection group (median [IQR] age, 60 [50-69] years; 91 [51.1%] men). The HAIP group was characterized by a higher percentage of bilobar disease (88.0% [n = 124] vs 34.3% [n = 61]), larger tumors (median, 8.4 cm vs 7.0 cm), and a higher proportion of patients with 4 or more lesions (66.7% [94] vs 24.2% [43]). Postoperative mortality after 30 days was 0.8% (95% CI, 0.0%-2.1%) in the HAIP group vs 6.2% (95% CI, 2.3%-9.7%) in the resection group (P = .01). The median OS for HAIP was 20.3 months vs 18.9 months for resection (P = .32). Five-year OS in patients with 2 or 3 lesions was 23.7% (95% CI, 12.3%-45.7%) in the HAIP group vs 25.7% (95% CI, 17.9%-37.0%) in the resection group. Five-year OS in patients with 4 or more lesions was 5.0% (95% CI, 1.7%-14.3%) in the HAIP group vs 6.8% (95% CI, 1.8%-25.3%) in the resection group. After adjustment for tumor diameter, number of tumors, and lymph node metastases, the hazard ratio of HAIP vs resection was 0.75 (95% CI, 0.55-1.03; P = .07).

Conclusions And Relevance: This cohort study found that patients with multifocal iCCA had similar OS after HAIP floxuridine chemotherapy vs resection. Resection of multifocal intrahepatic cholangiocarcinoma needs to be considered carefully given the complication rate of major liver resection; HAIP floxuridine chemotherapy may be an effective alternative option.

Citing Articles

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer.

Chen L, Vogel A, Hsu C, Chen M, Fang W, Pangarsa E ESMO Open. 2024; 9(8):103647.

PMID: 39232586 PMC: 11410730. DOI: 10.1016/j.esmoop.2024.103647.


Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer Database.

Schleimer L, Kalvin H, Ellis R, Kingham T, Soares K, DAngelica M Ann Surg Oncol. 2024; 31(10):6551-6563.

PMID: 39042229 DOI: 10.1245/s10434-024-15724-9.


Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.

Kuemmerli C, Hess V, Dutkowski P, Sinz S, Kessler U, Hess G Pharmacology. 2024; 109(2):86-97.

PMID: 38368862 PMC: 11008720. DOI: 10.1159/000537887.


Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies.

Ruff S, Pawlik T Front Oncol. 2024; 14:1321683.

PMID: 38344197 PMC: 10853998. DOI: 10.3389/fonc.2024.1321683.


Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers.

Zheng K, Wang X Ther Adv Med Oncol. 2024; 16:17588359231225040.

PMID: 38282664 PMC: 10822083. DOI: 10.1177/17588359231225040.


References
1.
ENSMINGER W, Gyves J . Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983; 10(2):176-82. View

2.
Spolverato G, Bagante F, Weiss M, Alexandrescu S, Marques H, Aldrighetti L . Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017; 115(6):696-703. DOI: 10.1002/jso.24569. View

3.
McMillan D, McArdle C . Epidemiology of colorectal liver metastases. Surg Oncol. 2007; 16(1):3-5. DOI: 10.1016/j.suronc.2007.04.008. View

4.
Kemeny N, Daly J, Oderman P, Shike M, Chun H, Petroni G . Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol. 1984; 2(6):595-600. DOI: 10.1200/JCO.1984.2.6.595. View

5.
Primrose J, Fox R, Palmer D, Malik H, Prasad R, Mirza D . Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20(5):663-673. DOI: 10.1016/S1470-2045(18)30915-X. View